Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Metzinger MN, Verghese C, Hamouda DM, Lenhard A, Choucair K, Senzer N, Brunicardi FC, Dworkin L, Nemunaitis J. Metzinger MN, et al. Among authors: senzer n. Oncology. 2019;97(2):59-74. doi: 10.1159/000500488. Epub 2019 Jul 1. Oncology. 2019. PMID: 31261152 Review.
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. Senzer N, et al. J Clin Oncol. 2004 Feb 15;22(4):592-601. doi: 10.1200/JCO.2004.01.227. Epub 2004 Jan 15. J Clin Oncol. 2004. PMID: 14726502 Clinical Trial.
Individualised cancer therapeutics: dream or reality?
Senzer N, Shen Y, Hill C, Nemunaitis J. Senzer N, et al. Expert Opin Ther Targets. 2005 Dec;9(6):1189-201. doi: 10.1517/14728222.9.6.1189. Expert Opin Ther Targets. 2005. PMID: 16300470 Review.
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Nemunaitis J, et al. Among authors: senzer n. J Clin Oncol. 2006 Oct 10;24(29):4721-30. doi: 10.1200/JCO.2005.05.5335. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966690 Clinical Trial.
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).
Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park ES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, De Pass AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, Dent P, Senzer N, Nemunaitis JJ, Fisher PB. Lebedeva IV, et al. Among authors: senzer n. Int J Oncol. 2007 Nov;31(5):985-1007. Int J Oncol. 2007. PMID: 17912425 Review.
Stathmin 1: a novel therapeutic target for anticancer activity.
Rana S, Maples PB, Senzer N, Nemunaitis J. Rana S, et al. Among authors: senzer n. Expert Rev Anticancer Ther. 2008 Sep;8(9):1461-70. doi: 10.1586/14737140.8.9.1461. Expert Rev Anticancer Ther. 2008. PMID: 18759697 Review.
120 results